SMC - March 2020 decisions

9 March 2020 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on ...

Read more →

SMC approves first two ‘ultra-orphan’ pathway meds

11 February 2020 - The Scottish Medicines Consortium has released its February guidance, advising six new medicines to NHS Scotland. ...

Read more →

SMC - February 2020 decisions

10 February 2020 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →

Supporting innovative medicines funding in Scotland

21 January 2020 - Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure ...

Read more →

SMC - January 2020 decisions

13 January 2020 - Medicines which can be used to treat prostate cancer, primary progressive multiple sclerosis, a rare form ...

Read more →

NICE and the SMC have published recommendations on Shionogi’s Mulpleo (lusutrombopag), approving its use for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures

12 December 2019 - Mulpleo (lusutrombopag) is the first licensed treatment to be made available through the National Health Service ...

Read more →

Ovarian cancer drug olaparib approved in Scotland as new treatment

9 December 2019 - A maintenance treatment for patients with advanced ovarian cancer has been approved for use in Scotland. ...

Read more →

SMC - December 2019 decisions

9 December 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →

Breast and kidney cancer drugs get approval for use across Scotland's NHS

11 November 2019 - Medicines for breast and kidney cancers are among five new drugs which can now be used ...

Read more →

SMC - November 2019 decisions

11 November 2019 - A medicine used to treat advanced breast cancer has today been accepted by the SMC for ...

Read more →

AbbVie’s Skyrizi (risankizumab) accepted for use within NHS Scotland

7 October 2019 - SMC recommendation based on results from four pivotal Phase 3 studies, UltIMMa-1, UltIMMa-2, IMMvent and IMMhance evaluating ...

Read more →

SMC - October 2019 decisions

7 October 2019 - Medicines which can be used to treat lymphoma, lung cancer, breast cancer and psoriasis have today been ...

Read more →

Vertex announces new access agreement with Scottish Government for Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)

12 September 2019 - Eligible patients in Scotland will immediately have access to Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor) in combination with ...

Read more →

SMC U-turn for Vertex’s CF drugs

12 September 2019 - Vertex has announced that following a change of heart by the SMC, eligible cystic fibrosis patients ...

Read more →

SMC - September 2019 decisions

9 September 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today ...

Read more →